Genetically engineered cell and application thereof
AssigneeCrage Medical Co., Limited
InventorsZonghai Li, Hong Luo, Hua Jiang, Huamao Wang
Life of this patent
Estimating the term…
Abstract
Disclosed in the present invention is a genetically engineered cell, expressing an exogenous receptor that specifically binds to a target antigen and exogenous CCL21, and capable of further expressing an IL-7R binding protein or exogenous IL-7 that promotes cell proliferation. Also disclosed are an expression construct comprising an exogenous CCL21 expression cassette, and a vector containing same, a virus, and a pharmaceutical composition comprising said cell. Also disclosed is an application for the cell, the expression construct, the vector, and the virus in the preparation of drugs for inhibiting tumours or inhibiting pathogens.
Claims38
A genetically engineered T cell, wherein the cell expresses an exogenous receptor specifically binding to a target antigen, an-exogenous CCL21, a protein promoting the proliferation of the cell, which is an exogenous IL-7, and wherein the cell does not express an exogenous CCL19.
An expression construct, comprising sequentially connected:
- an expression cassette 1 comprising a nucleic acid sequence encoding an exogenous receptor specifically binding to a target antigen, an expression cassette 2 comprising a nucleic acid sequence encoding an exogenous IL-7, and an expression cassette 3 comprising a nucleic acid sequence encoding an exogenous CCL21.
A method for improving the viability of T cells expressing a chimeric receptor in an individual, comprising expressing an exogenous CCL21 and an exogenous IL-7 in the T cells.
A kit, comprising kit A and kit B, wherein the kit A comprises genetically engineered T cells, and the T cells express an exogenous receptor specifically binding to a target antigen;
- and the kit B comprises CCL21, and a protein that promotes the proliferation of the cells, which is IL-7.
Dependencies are inferred from the claim text.